Search Results for: DNA VACCINES MARKET DNA Vaccines
Articles
DNA VACCINES MARKET – DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Global Market for DNA Vaccines to Reach $2.7 Billion August 25, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Global Market for DNA Vaccines to Reach $2.7 Billion August 21, 2014
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...Aptamers Market is Expected to Reach $342 million April 27, 2023
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the...IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System November 10, 2022
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis January 6, 2022
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing May 6, 2021
Catalent and Promethera Biosciences recently announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its….
AstraZeneca’s & J&J’s COVID-19 Vaccines Manufacturing Face Viral Vector Shortages March 25, 2021
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines,...AnGes & Brickell Biotech Announce Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 September 9, 2020
AnGes, Inc. recently announced a collaboration agreement with Brickell Biotech, Inc. through which Brickell has the right to develop AnGes’ proprietary….
Up to 6 New HBV Drugs Set to Launch by 2027, With China Driving Market Growth May 30, 2019
Within the next 10 years, up to 6 new drugs are projected to be approved for the treatment of chronic...Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments February 27, 2019
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and...Inovio’s DNA-Based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation July 7, 2017
Inovio Pharmaceuticals, Inc. recently announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection...PROTEIN THERAPEUTICS MARKET – Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
NIH Using PharmaJet in DNA Vaccine Clinical Trial August 10, 2016
PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine...Cobra Biologics & Touchlight Collaborate on Production of Next-Generation DNA Constructs June 14, 2016
Cobra Biologics Ltd and Touchlight are collaborating on a project to optimize the manufacture of Adeno-Associated Virus (AAV) vectors used...Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion May 31, 2016
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC...SINGLE-USE MARKET – Rise of Single-Use Technologies & Systems in Biopharmaceuticals November 19, 2015
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Latest Frost Reports: Next-Generation Therapeutics for Infectious Diseases; Orphan Drugs Market March 31, 2014
Next-Generation Therapeutics The available antivirals for commonly occurring infections, such as respiratory syncytial virus (RSV) and influenza are characterized by...Ocugen Announces FDA Clearance of IND Amendment to Initiate Phase 3 Clinical Trial – First Gene Therapy to Enter Phase 3 With a Broad Retinitis Pigmentosa Indication April 8, 2024
Ocugen, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) amendment to initiate a Phase...
